The diverse modification of N-butyl-N-(4-hydroxybutyl) nitrosamine induced carcinogenesis in urinary bladder by dibromodulcitol and dianhydrodulcitol

The effects of intravesical therapy with adriamycin, 1.6-dibromo-1.6-dideoxydulcitol (DBD) or with 1.6-dianhydrodulcitol (DAD) on bladder carcinogenesis were investigated in rats. To induce premalignant lesions in the urinary bladder female Sprague-Dawley rats received 0.05% N-butyl-N-(4-hydroxybuty...

Full description

Saved in:
Bibliographic Details
Published inActa morphologica Hungarica Vol. 40; no. 1-4; p. 187
Main Authors Szende, B, Jeney, A, Institoris, L
Format Journal Article
LanguageEnglish
Published Hungary 1992
Subjects
Administration, Intravesical
Administration, Oral
Animals
Butylhydroxybutylnitrosamine - toxicity
Carcinogens - pharmacology
Carcinoma, Transitional Cell - chemically induced
Carcinoma, Transitional Cell - pathology
Dianhydrogalactitol - administration & dosage
Dianhydrogalactitol - pharmacology
Doxorubicin - administration & dosage
Doxorubicin - pharmacology
Female
Mitolactol - administration & dosage
Mitolactol - pharmacology
Papilloma - chemically induced
Papilloma - pathology
Precancerous Conditions - chemically induced
Precancerous Conditions - pathology
Rats
Rats, Sprague-Dawley
Urinary Bladder Neoplasms - chemically induced
Urinary Bladder Neoplasms - pathology
Online AccessGet more information

Cover

More Information
Summary:The effects of intravesical therapy with adriamycin, 1.6-dibromo-1.6-dideoxydulcitol (DBD) or with 1.6-dianhydrodulcitol (DAD) on bladder carcinogenesis were investigated in rats. To induce premalignant lesions in the urinary bladder female Sprague-Dawley rats received 0.05% N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in their drinking water for 4 weeks and then post-treated intravesically with one of the antitumor drugs and examined once a week for 3 months. These antitumor drugs in healthy rats (i.e. without the pre-administration of BBN) did not cause any significant morphological changes in the urinary bladder after intravesical application once a week for 3 months. In the applied dose BBN alone induced only premalignant lesions in the urinary bladder. However, neoplastic lesions occurred in the groups treated with BBN and adriamycin (9 papillomas and 3 carcinomas in 14 animals). Similarly intravesical application of DBD after BBN administration resulted 5 carcinomas among the 11 animals. On the contrary no urinary bladder tumor was found in the animals treated with BBN and DAD. As DAD is one of the conversion products of DBD it is conceivable that the difference between DBD and DAD action may be due to the formation of other solvolytic product from DBD than DAD.
ISSN:0236-5391